...Pharma Inc., Kotobuki Pharmaceutical Co. and Merck & Co. Inc. market the SGLT2 inhibitor Suglat ipragliflozin...

...of new products and expanded labels of gastrointestinal drug Linzess linaclotide and diabetes drug Suglat ipragliflozin...
...Tokyo:4503) Tokyo, Japan Business: Other Jennie Walters CK-107, CK-2127107 Constella, Linzess, linaclotide (ASP0456, MD-1100) fezolinetant (ESN364, ESN-364) gilteritinib (ASP2215) Suglat, ipragliflozin (ASP1941) Xtandi...

...of new products and expanded labels of gastrointestinal drug Linzess linaclotide and diabetes drug Suglat ipragliflozin...

...growing skeletons Merck & Co. Inc. (NYSE:MRK) / Astellas Pharma Inc. (Tokyo:4503) Japan approves Sujanu sitagliptin/ipragliflozin...

...of dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor Januvia sitagliptin and sodium-glucose cotransporter 2 (SGLT2) inhibitor Suglat ipragliflozin...
...Kisplyx (Other) Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Suglat, ipragliflozin (ASP1941) Amicus...

...of dipeptidyl peptidase-4 (DPP-4; CD26) inhibitor Januvia sitagliptin and sodium-glucose cotransporter 2 (SGLT2) inhibitor Suglat ipragliflozin. Chris...
...Kisplyx (Other) Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Shingrix (GSK1437173A, hz/su, Herpes zoster vaccine) Suglat, ipragliflozin (ASP1941) Amicus...

...with Kotobuki launched Suglat ipragliflozin in Japan to treat Type II diabetes. The partners said Suglat...
...2 (SGLT2) inhibitor approved for the indication in the country. Astellas will manufacture and sell Suglat...
...low-dose package and ¥205.50 ($2.01) for the high-dose package. Last year, Astellas discontinued development of ipragliflozin...

...Astellas said Japan's Ministry of Health, Labor and Welfare (MHLW) approved Suglat ipragliflozin to treat Type...
...the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat...
...Pharma Inc. (Tokyo:4503), Tokyo, Japan Kotobuki Pharmaceutical Co. , Tokyo, Japan Product: Suglat ipragliflozin ( ASP1941...

...Tokyo:4503) said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an NDA for Suglat ipragliflozin...
...the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the indication in Japan. Astellas co-developed Suglat...
...Merck & Co. Inc. (NYSE:MRK) will co-promote the product in Japan. Astellas discontinued development of ipragliflozin...

...Lilly and Co. , luseogliflozin in Japan from Taisho Pharmaceutical Holdings Co. Ltd. , and ipragliflozin...